MEF PKCe KO KI Cell Line is a clonal MEF line derived from PKCepsilon knock-out embryos subsequently transfected to re-express PKCe through stable transfection with pcDNA3 CMV/IE hygo+ PKCe.
| Inventor | Institute |
|---|---|
| Peter Parker | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| SKU: | 151663 |
|---|---|
| Product description: | MEF PKCe KO KI Cell Line is a clonal MEF line derived from PKCepsilon knock-out embryos subsequently transfected to re-express PKCe through stable transfection with pcDNA3 CMV/IE hygo+ PKCe. Matched isogenic cell line which is null for PKCe is also available. Useful for studying the role of PKCe in various biological processes |
| Production details: | MEFs were derived from PKCe knockout embryos. Polyclonal PKCeKO cells were transfected with pcDNA3 CMV/IE hygro+ PKCe vector using calcium phosphate. Clonal stable cell lines were selected using limiting dilution. The vector was contructed by replacing the promoter region in pCMV hygro+ with a 2.1kb CMV/IE promoter derived from p63d. Mouse cDNA encoding full-length PKCe (3.3kb fragment) was ligated to the modified pcDNA3 CMV/IE hygro+ vector. |
| Cellosaurus ID: | CVCL_AS82 |
| Disease: | Cancer |
| Cat. #: | 151663 |
|---|---|
| Provenance and Ownership: | The MEF PKCe KO KI Cell Line is owned by Cancer Research UK. CancerTools supplies the MEF PKCe KO KI Cell Line under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing MEF PKCe KO KI Cell Line directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Unit size: | 1×10^6 cells / vial |
| Organism: | Mouse |
| Tissue: | Embryo |
| Model: | Transgenic |
| Growth properties: | Normal phenotype |
| Format: | Frozen |
|---|---|
| Shipping conditions: | Dry ice |
| Growth medium: | Cells were selected, and are routinely cultured in DMEM + 10% FCS and 100ug/ml hygromycin at 30degC in a 10% CO2 atmosphere |
| References: |
Cited by 24 subsequent publications including: Ivaska, J. et al. 2002. EMBO J. 21:3608-19.PMID: 12110574 Kermorgant, S. et al. 2004. EMBO J. 23: 3721:34. PMID 15385963 Pardo et al. 2006. EMBO J. 25(13):3078-88. PMID: 16810323. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.